Ying Jin, Lan Zhang, Binchen Mao, Guoqin Zhai, Zhongliang Li, Meng Qiao, Annie An, Juan Zhang, Sheng Guo, WenQing Yang, and Qian Shi
In vitro cell-based screens frequently used in oncology to quickly identify responsive cells, often fail in immuno-oncology, due to immunotherapeutics targeting the complex host immune system.
While an in vivo screen using syngeneic models could be an alternative, this would usually be cost prohibitive. CrownBio has therefore developed the first cost-effective in vivo screening system to test novel immuno-oncology drug candidates utilizing multiple syngeneic models – MuScreen.
Cost effectiveness is afforded by test agents from multiple clients being run simultaneously during each screen, sharing vehicle and other common groups, which also reduces animal usage. Antitumor efficacy (via tumor growth inhibition) is evaluated as a final readout with optional FACS and IHC.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-02-19
2021-10-28
landing_page
PDX/Databases